Since antisera to rat and mouse ax-foetoprotein (AFP) are found to induce cytotoxic effects on AFP-producing rat or mouse hepatocellular carcinoma cells in vitro and in vivo (Tsukada et al., 1974a; Mizejewski & Allen, 1974 ) further analysis of this phenomenon was undertaken. The observation of AFP on the cell surface of AFPproducing hepatoma cells by the membrane immunofluoresence technique is clearly indicative of the formation of AFP: anti AFP antibody complexes on the plasma membrane (Tsukada et al., 1974a; Mizejewski & Allen, 1978) .
In in vitro and in vivo studies, selective decrease of high AFP-producing cells as well as insufficient uptake of energy sources are observed when AFPproducing rat hepatoma cells were treated with anti-AFP antibodies (Tsukada et al., 1974b; Wepsic et al., 1980; Ohkawa et al., 1984) . Affinity-purified antibodies to AFP fully retained their cytotoxic activities .
Recently, in order to increase the cytotoxic effect of anti-AFP antibody on the tumour target cells, we have successfully developed specific targeting chemotherapy using anti-AFP antibody with which daunorubicin (DM) was conjugated via periodateoxidized dextran (Tsukada et al., 1982a (Tsukada et al., , 1982b .
Further, we have developed a new method of conjugating DM with antibody using a novel thiol derivative of poly-L-glutamic acid (PLGA) as the intermediate drug carrier Kato et al., 1984 (Hirai et al., 1981 , Nishi & Hirai, 1972 .
The high AFP-producing human hepatocellular carcinoma Li-7 was maintained by serial passage in athymic BALB/c nude mice (Hirohashi et al., 1979) . The Li-7 tumour grows as well-vascularized soft masses whose volume is expressed as V= [major diamater (mm) (Ovejera, et al., 1978) .
In the test and control conjugates, DM was linked via PLGA to aAFP and normal horse immunoglobulin (nlg), respectively. These conjugates, abbreviated as aAFP-PLGA-DM and nIg-PLGA-DM, were prepared with the use of an appropriate Ig by the method detailed previously . Briefly, for the preparation of PLGA having a single thiol group at its N-terminal (HS-PLGA), the masked thiol, 2-pyridyldithio group was introduced to the Nterminal of PLGA (average mol. wt., 17,000 as Na salt; Sigma Chemical Co., St Louis, Mo., USA) by the action of N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP; Pharmacia Chemicals AB, Uppsala, Sweden), and the free thiol group was generated from the masked form with dithiothreitol (DTT). HS-PLGA free from unreacted PLGA was isolated by affinity chromatography by the use of thiopropyl sepharose 6B resin. The thiol group of the purified HS-PLGA was protected as the 2-pyridyldithio group by the action of 2-pyridyldisulfide, and DM was linked to the PLGA derivative (Py-ss-PLGA) with the aid of l-ethyl-3-(3-dimethylaminopropyl) carbodiimide (Py-ss-PLGA-DM). The thiol group-reactive maleimide group was introduced to Ig with N-succinimidyl 4-(N-maleimido)butyrate, and the resulting modified Ig was treated with the DM-linked HS-PLGA (HS-PLGA-DM) whose thiol group had been regenerated from Py-ss-PLGA-DM with DTT. The conjugates thus formed were purified by large-scale disc polyacrylamide gel electrophoresis.
For the experiment, 0. (Mancini et al., 1965; Nishi & Hirai, 1976) . Prior to the conjugate therapy, the optimal effective dose of DM to Li-7 growing in nude mice was determined. Nude mice inoculated with 106 cells of Li-7 on day 0 were treated with PBS or 5, 10, or 20,pg of DM starting from day 14 at 5-day intervals for a total of 4 times. On day 30, mice were killed and RTS, body weight and serum AFP level were measured.
The anti-AFP and control normal conjugates were prepared by conjugation of DM with aAFP and nIg with the use of a single thiol group-bearing PLGA derivative as the intermediate drug carrier. The DM-to-Ig binding ratios and other pertinent chemical data of the conjugates prepared and evaluated are shown in Table I .
The RTS on day 30 of nude mice injected with PBS was 9.8, whereas those of nude mice treated with 5, 10 or 20pg of DM were 7.2, 2.8 and 2.2, respectively, which indicated 27, 72 and 78% inhibition of tumour growth as shown in Table II . aThe methods for quantitation of DM, the 2-pyridyldithio group and Ig are the same as those described in the previous paper . bDetermined by the end-group (2-pyridyldithio) analysis with respect to a lyophilized aliquot of Py-ss-PLGA.
cThe DM content (mol) was determined spectrophotometrically, and the PLGA content by end-group analysis.
dThe average percentage of the DM-linked carboxyl groups among the total number of the carboxyl groups in PLGA.
eCalculated by division of the DM-to-Ig binding ratio by the DM-to-PLGA binding ratio. 
4.14+0.06).
A striking suppression of tumour growth was observed in the group of mice treated with a AFP-PLGA-DM i.e. there was essentially no proliferation of Li-7 and the inhibition of tumour growth at day 49 was statistically significant compared even with the RTS of the group of mice treated with aAFP plus DM (P<0.05) (RTS: aAFP plus DM, 3.25+0.2; aAFP-PLGA-DM, 1.14 ± 0.03).
No significant difference of rate of increase in body weight was observed between the control PBS group and the DM and aAFP-PLGA-DM groups except slight reduction of body weight in the drugtreated groups within one week after the initial treatment (Figure iB) .
Serum AFP levels were well correlated with the growth of Li-7 as an indicator of cell proliferation. A high AFP level ranging from 380 to 430pgml-1 was found in the groups of mice treated with PBS (432 + 63) or nlg (38 1+ 61). Moderately elevated levels of AFP were detected in the groups of mice treated with DM (71+5.4), PLGA-DM (62+4.9) or nlg-PLGA-DM (35+2.8). A low level of AFP ranging from 13 to 67ngml-1 was observed in the groups of mice treated with aAFP (13 + 1.2), aAFP plus DM (53+4.4) or aAFP plus PLGA-DM (67 ±5.9), although the RTS curves were almost the same as those of mice treated with DM, PLGA-DM or nlg-PLGA-DM. The group of mice treated with aAFP-PLGA-DM showed an extremely low level of AFP (2.2+0.18ngml-1), which was estimated as the normal AFP level.
It has been demonstrated that antibodies to rat AFP exhibit cytotoxicity to AFP-producing hepatocellular carcinoma cells in rat both in vitro and in vivo (Tsukada et al., 1974 : Wepsic et al., 1980 . The positive imaging by radioimmunodetection as well as positive immunostaining of cell surface by antibody to AFP indicates that the antibody molecules localize to the tumour by coupling to the cell surface-associated AFP molecules (Koji et al., 1980; Tsukada et al., 1974) . Recently, the targeting chemotherapy by polyclonal or monoclonal antibodies to tumour-associated antigens has been extensively studied (Latif et al., 1980; Embleton et al., 1981; Bernhard et al., 1983; Garnett et al., 1983) . Similar approaches have been made utilizing purified antibody to rat AFP and anticancer drugs such as daunorubicin (DM) and mitomycin C (MMC) (Tsukada et al., 1982a; 1982b; . Recently our-laboratory (Kato et al., 1983) developed a new method of conjugation of DM with antibody with a single thiol group-bearing PLGA derivative as intermediate drug carrier and the anti-rat AFP antibody-PLGA-DM conjugate prepared by this method showed a potent antitumour activity against the AFP-producing ascites hepatocellular carcinoma cells AH66 growing in DONRYU rats .
The antitumour activity of the present aAFP-PLGA-DM conjugate prepared by the same new method with the use of antibody to human AFP was assessed in terms of the suppressive effect on growth of the AFP-producing human tumour Li-7 in nude mice in comparison with various test materials ( Figure IA) . The effect of the conjugate was greater than those of all other test materials. The maintenance of low AFP level in the group of mice treated with aAFP, aAFP plus DM, and aAFP plus PLGA-DM was probably caused by two factors viz. the selective decrease of AFP highproducing tumour cells and of remaining antibody to AFP (Tsukada et al., 1974b; 1982a) (Figure 2 Time (d) Figure 1 Therapeutic activity of anti-human AFP-PLGA-DM. Li-7 cells, 1-1.5 x 106 were transplanted into nude mice on day 0. aAFP-PLGA-DM (aAFP 142 g, DM 10kg mouse/injection) and other test materials were administered i.p. twice a week for a total of 8 times from day 17 to day 42 and RTS was determined at the same time and on day 49. Average body weight of each group was determined by the same schedule as that for the administration of the test materials. The average body weight on day 0 was 25. This is the first study ever reported to use the system of antibody to human AFP: human AFPproducing tumour with very encouraging results. The utilization of monoclonal antibody to human AFP for conjugation with DM may be possible since a conjugate of DM with a monoclonal antibody to rat AFP proved to be as effective as the corresponding polyclonal antibody conjugate (Tsukada et al, 1982b; . The overall conclusion from the present study is that aAFP-PLGA-DM exhibits a potent antitumour activity toward a human AFP-producing neoplasm in nude mice by the homing effect of antibody. The result should be regarded as bringing the targeting of chemotherapy one step closer to clinical trials.
